Agenus is a biotechnology company founded in 1994 by Garo H. Armen and Pramod K. Srivastava. The company focuses on cancer vaccines, immunotherapeutics, adjuvants and infectious disease treatments. Antigenics became a public company in February 2000 on the NASDAQ exchange with the ticker symbol AGEN. In 2000 Agenus acquired Aquila Biopharmaceuticals and in 2001 also acquired Aronex Pharmaceuticals. Agenus has over 80 U.S. patents, many of which relate to its proprietary heat shock protein technology upon which its experimental cancer vaccine Oncophage is built.
|Founders:||Garo H. Armen|
|Industries:||Biological Product (except Diagnostic) Manufacturing, Biotechnology|